Which CRC Regimens Are More Likely to Harm Kidneys?

After analyzing various treatments for metastatic colorectal cancer (CRC), researchers zeroed in on FOLFIRI + bevacizumab. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/974095?src=rss